We offer FREE SHIPPPING on all orders!
We offer FREE SHIPPPING on all orders!
| THIS PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for invitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly prohibited by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food, or cosmetic. |
Boldenone Cypionate 200 is an injectable anabolic-androgenic steroid preparation commonly described as containing 200 mg of boldenone cypionate per milliliter. It combines the steroid boldenone with a cypionate ester, producing a relatively long-acting formulation.
Boldenone itself is structurally related to testosterone. However, boldenone cypionate is not an FDA-approved medication for human use, and unlike established testosterone products, it does not have a standardized human therapeutic dosing framework.
Boldenone cypionate consists of boldenone attached to a cypionate ester.
The cypionate ester primarily affects the rate at which boldenone is released following injection. Once the ester is cleaved, the active steroid is boldenone.
Boldenone is closely related structurally to testosterone, differing by an additional double bond between carbon positions 1 and 2. This relatively small structural difference changes its metabolism and pharmacological characteristics.
A concentration of:
Boldenone Cypionate: 200 mg/mL
means each milliliter contains 200 mg of the complete esterified compound.
Because the cypionate ester contributes part of its molecular weight, 200 mg of boldenone cypionate does not equal 200 mg of free boldenone.
Based on molecular weights, boldenone cypionate is approximately 68% boldenone by weight, so 200 mg corresponds to roughly 136 mg of boldenone, with the remainder representing the cypionate ester.
This is a chemical comparison and not a human dosing recommendation.
Once released from its ester, boldenone binds to androgen receptors.
Androgen receptors are found in skeletal muscle, reproductive tissues, skin, hair follicles and numerous other tissues. Their activation alters gene transcription and influences protein metabolism, nitrogen balance and other androgen-dependent physiological processes.
Boldenone therefore has both anabolic and androgenic activity.
Boldenone can promote anabolic signaling in skeletal muscle through androgen-receptor activation.
Potential effects of substantial androgen exposure include increased protein synthesis, improved nitrogen retention and increases in lean tissue.
However, descriptions of boldenone as a relatively "mild" anabolic steroid can be misleading. A compound can produce less obvious androgenic or estrogenic effects while still significantly affecting cardiovascular, hematologic, reproductive and endocrine physiology.
Boldenone is much more commonly associated with boldenone undecylenate, historically known by the veterinary brand Equipoise.
The active steroid in both compounds is boldenone.
The difference is the ester:
Boldenone Cypionate uses a cypionate ester and has a long-acting release profile.
Boldenone Undecylenate uses the larger undecylenate ester and generally produces an even more prolonged release.
The ester changes pharmacokinetics rather than converting boldenone into a different anabolic steroid.
Boldenone and testosterone are structurally related but distinct steroids.
Both activate androgen receptors, but testosterone is the body's primary endogenous male androgen and performs numerous essential physiological functions.
Boldenone should therefore not be considered simply another testosterone ester.
Using boldenone can suppress endogenous testosterone production without necessarily reproducing the complete physiological role of testosterone.
Boldenone can undergo aromatization, although its estrogenic behavior differs from testosterone.
It should therefore not be described as completely non-aromatizing.
The degree of estrogen-related effects depends on exposure, individual metabolism and any other hormones being used concurrently.
Potential hormone-related symptoms during anabolic-steroid exposure should not automatically be attributed to a single laboratory value or treated empirically without appropriate evaluation.
Boldenone possesses androgenic activity.
Potential androgen-related effects include:
Genetic sensitivity plays a major role in determining the severity of these effects.
One particularly important consideration with boldenone is its association with erythropoiesis, or red blood cell production.
Androgen exposure can increase:
An excessive hematocrit elevation can increase blood viscosity and become medically significant.
This is an important reason that CBC monitoring is relevant in someone exposed to anabolic-androgenic steroids. Symptoms such as severe headache, chest pain, unusual shortness of breath, neurological symptoms or significant blood-pressure elevation require medical evaluation rather than being assumed to be routine steroid effects.
Potential cardiovascular concerns associated with anabolic-androgenic steroid exposure include:
Overall risk depends on duration, total exposure, concurrent compounds, genetics, age, cholesterol, blood pressure, smoking and underlying cardiovascular health.
A relatively gradual or visually "clean" anabolic effect does not imply cardiovascular safety.
Boldenone can suppress the hypothalamic-pituitary-gonadal axis.
External androgen exposure creates negative feedback that reduces LH and FSH secretion.
As LH decreases, the testes reduce endogenous testosterone production.
Possible consequences include reduced natural testosterone production, decreased testicular function, reduced testicular volume, libido or sexual-function changes and impaired fertility.
Suppression of LH and FSH can interfere substantially with normal sperm production.
Possible consequences include reduced sperm concentration, very low sperm counts and potentially azoospermia.
Recovery after discontinuation varies among individuals and cannot reliably be predicted from the ester or duration alone.
Anyone concerned about future fertility should discuss fertility testing and preservation with an appropriate medical specialist.
Increased appetite is frequently associated with boldenone in bodybuilding discussions.
However, the magnitude and consistency of this effect in humans have not been well established through controlled clinical research.
It is therefore better regarded as a commonly reported effect rather than a predictable pharmacological outcome.
Injectable boldenone cypionate is not a conventional 17-alpha-alkylated oral anabolic steroid, so its hepatic profile differs from many oral anabolic steroids.
Nevertheless, abnormal liver tests during anabolic-steroid exposure should still be medically evaluated.
Kidney health can also be affected indirectly through factors such as elevated blood pressure and hematocrit. Kidney laboratory results can be more difficult to interpret in highly muscular individuals because creatinine is influenced by muscle mass, exercise, diet, hydration and creatine use.
Persistent renal abnormalities or protein in the urine warrant evaluation.
Injectable preparations introduce risks independent of boldenone itself, including:
Unregulated products create additional uncertainty concerning sterility, contamination, actual concentration and whether the labeled compound is actually present.
Progressively worsening redness, warmth, severe pain, drainage, significant swelling or fever following an injection warrants medical attention.
Potential adverse effects associated with boldenone/AAS exposure include acne, oily skin, androgenic hair loss, increased hematocrit, changes in blood pressure, unfavorable cholesterol changes, suppression of endogenous testosterone, reduced fertility, sexual-function changes and injection-related complications.
The hematologic and cardiovascular effects deserve particular attention because they may occur without obvious outward symptoms.
Compound: Boldenone Cypionate
Common Concentration: 200 mg/mL
Drug Class: Anabolic-androgenic steroid
Active Steroid: Boldenone
Ester: Cypionate
Release Profile: Long acting
Approximate Boldenone Content: About 136 mg boldenone per 200 mg boldenone cypionate
Anabolic Activity: Yes
Androgenic Activity: Yes
Aromatization: Possible
Can Increase Red Blood Cell Production: Yes
Can Increase Hematocrit: Yes
Suppresses Natural Testosterone: Yes
Can Impair Fertility: Yes
FDA-Approved Human Use: No
Boldenone Cypionate 200 is a long-acting esterified form of boldenone, a synthetic anabolic-androgenic steroid structurally related to testosterone. The cypionate ester provides prolonged release, while boldenone itself produces anabolic and androgenic activity through androgen-receptor signaling.
It is particularly important not to equate a reputation for comparatively gradual muscle gain or lower visible water retention with safety. Boldenone can suppress natural testosterone and fertility, adversely affect cholesterol and blood pressure, produce androgenic effects and meaningfully increase red blood cell production and hematocrit.
Unlike standard testosterone replacement medications, boldenone cypionate has no established FDA-approved human therapeutic use or standardized human dosing regimen, making products sold for human performance use especially uncertain in terms of concentration, purity, sterility and safety.
We do not accept returns or issue refunds for any reason, beside manufacturing defects.
Feel free to contact us if you have any questions or concerns about our Return Policy.
